Evidence map›Paper›PMID 41078116›Full record

ArticleJournal of cellular and molecular medicine2025

BNIP3L/BNIP3-Mediated Mitophagy Contributes to the Maintenance of Ovarian Cancer Stem Cells.

Na Li, Tejinder Pal Khaket, Yajing Yang, Linzhou Wang, Shurui Cai, Aidan Li, Elsa Wani, Jessica Miao, Nan Zhang, Qingfei Zheng and 5 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Na LiDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Tejinder Pal KhaketDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Yajing YangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Linzhou WangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Shurui CaiDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Aidan LiDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Elsa WaniDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Jessica MiaoDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Nan ZhangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Qingfei ZhengDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Junran ZhangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Xuefeng LiuDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Selvendiran KaruppaiyahDepartment of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Dehua PeiDepartment of Chemistry and Biochemistry, College of Biology, The Ohio State University, Columbus, Ohio, USA.
Qi-En WangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-3759-2148

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Macrocyclic Peptidyl Inhibitors of NEMO-IKK InteractionR01CA234124 · NCI · OHIO STATE UNIVERSITY · PI PEI, DEHUA, WANG, QIEN · 2019 to 2023
$2.1M
Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancerR01CA248027 · NCI · OHIO STATE UNIVERSITY · PI Qien Wang · 2021 to 2026
$1.7M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA234124NCI NIH HHS R01 CA248027NIH HHS R01CA234124NIH HHS R01CA248027
6 · The paper itself

Abstract

Ovarian cancer remains the most lethal gynaecological malignancy, with tumour recurrence and chemoresistance posing significant therapeutic challenges. Emerging evidence suggests that cancer stem cells (CSCs), a rare subpopulation within tumours with self-renewal and differentiation capacities, contribute to these hurdles. Therefore, elucidating the mechanisms that sustain CSCs is critical for improving treatment strategies. Mitophagy, a selective process for eliminating damaged mitochondria, plays a key role in maintaining cellular homeostasis, including CSC survival. Our study demonstrates that ovarian CSCs exhibit enhanced mitophagy, accompanied by elevated expression of the mitochondrial outer membrane receptors BNIP3 and BNIP3L. Knockdown of BNIP3 or BNIP3L significantly reduces mitophagy and impairs CSC self-renewal, indicating that receptor-mediated mitophagy is essential for CSC maintenance. Mechanistically, we identify that hyperactivated NF-κB signalling drives the upregulation of BNIP3 and BNIP3L in ovarian CSCs. Inhibition of NF-κB signalling, either via p65 knockdown or pharmacological inhibitors, effectively suppresses mitophagy. Furthermore, we demonstrate that elevated DNA-PK expression contributes to the constitutive activation of NF-κB signalling, thereby promoting mitophagy in ovarian CSCs. In summary, our findings establish that BNIP3/BNIP3L-mediated mitophagy, driven by DNA-PK-dependent NF-κB hyperactivation, is essential for CSC maintenance. Targeting the DNA-PK/NF-κB/BNIP3L-BNIP3 axis to disrupt mitochondrial quality control in CSCs represents a promising therapeutic strategy to prevent ovarian cancer recurrence and metastasis.

Indexed as

Membrane ProteinsMitochondrial ProteinsMitophagyNeoplastic Stem CellsOvarian NeoplasmsProto-Oncogene ProteinsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceMitochondriaNF-kappa BSignal TransductionTumor Suppressor ProteinsBNIP3L protein, humanBNIP3 protein, humanMembrane ProteinsMitochondrial ProteinsNF-kappa BProto-Oncogene ProteinsTumor Suppressor ProteinsBNIP3BNIP3Lcancer stem cellsDNA‐PKmitophagyNF‐κBovarian cancer

Identifiers

PMID41078116
PMCPMC12516242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.